Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
POET Technologies enters the week under pressure from multiple directions — the stock fell nearly 14% in five sessions while insiders sold at the top, and nearly one-in-five shares in the free float remains borrowed against it.
The insider activity is the most pointed signal this week. On August 7, CEO Suresh Venkatesan sold 170,073 shares at $8.93, collecting $1.52 million. CFO Thomas Mika sold 45,799 shares the same day for $409,000. A controller followed with a further $131,000 sale on August 10. These were open-market disposals, not option exercises — and they came on the same day a clutch of equity awards was granted to the same executives. The net 90-day insider position is technically positive at roughly 590,000 shares, but that figure is dominated by the award grants at zero cost. Strip those out, and the picture is one of C-suite monetisation at prices now well above where the stock trades.
Short positioning adds a second layer of pressure. At 18.9% of the free float, short interest is firmly in elevated territory, and while it has eased about 3.4% over the past week and 6.2% over the past month, it remains a meaningful overhang. Borrow availability has tightened to 30.5% — roughly one share available for every three already lent out, and well below the 52-week tightest of 2.4% that this name has touched before. Cost to borrow is modest at just under 1%, up about a third from a month ago but not yet punishing for short-sellers. The setup means shorts face some constraint on adding but no acute squeeze pressure: availability is tight but not critically so, and the borrow cost gives no urgency to cover. Options reinforce the calm — the put/call ratio has drifted to 0.18, sitting almost exactly on its 20-day average and near the lower end of the 52-week range, suggesting little incremental hedging demand despite the week's sell-off.
The Street picture is stale but directionally relevant. The most recent analyst actions on record are from late 2024 — Northland Capital Markets and Craig-Hallum both carried positive ratings with targets in the $5.50–$7.00 range at that point, well below where the stock subsequently traded. A mean price target of $17.50 is cited in the data, but given the last recorded analyst action dates from December 2024 and the stock has moved substantially since, that figure should be treated cautiously rather than as a live consensus. What is clear is that formal analyst coverage remains thin. The ORTEX short score of 66.2 ranks in the bottom 4th percentile on the short-score factor, flagging this as a name where bearish data points cluster. Momentum has been strong over longer timeframes — a prior note cited relative-strength readings well above the semiconductor peer group — but the past month shows only a 1.4% decline masking a sharper recent slide.
Peers offered little comfort this week. RMBS fell 9.5% and IPWR dropped 9.2% over the same five sessions, suggesting sector-level selling rather than POET-specific news alone. The company's next earnings event is pencilled in for November 13. The August 13 release produced an 8% one-day gain that faded into a 6.8% loss over the following five days — a pattern of initial optimism giving way to selling that will be worth watching when November arrives. The most recent print, on August 20, carried a 2.3% one-day decline.
With insiders having cashed out near $9, short interest still above 18% of float, and availability tightening back toward the 27–30% range it has occupied for much of August, the next material data point to monitor is whether short interest continues its gradual decline or stabilises — and whether the borrow market tightens further as the stock searches for a floor.
See the live data behind this article on ORTEX.
Open POET on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
